Literature DB >> 1881241

Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats.

C Guettet1, N Rostaqui, D Mathé, B Lecuyer, N Navarro, B Jacotot.   

Abstract

Male adult Wistar rats received daily (at 9 a.m. and 5 p.m.) 10 micrograms of zinc-protamine glucagon by subcutaneous injection for 8 days. Plasma cholesterol levels were decreased by 36% in fed rats, 33% in cholesterol-fed rats and by 55% in fasted rats. Lipoproteins were separated into 22 fractions by ultracentrifugation using a density gradient. Glucagon administration decreased the cholesterol content in all lipoproteins except low density lipoprotein (LDL1) (1.006-1.040) and very low density lipoprotein (VLDL) from cholesterol-fed rats. The main decrease (-57 to -81%) was observed in 1.050-1.100 g/mL lipoproteins (LDL2 and HDL2), which contained a large amount of apo E, while HDL3 cholesterol was not affected. Triacylglycerol levels were decreased only in chylomicrons and VLDL (-70%) of fed and cholesterol-fed rats, while plasma and lipoprotein triacylglycerol levels were not changed in fasted rats treated with glucagon. In normally fed rats glucagon administration increased by 42% the fractional catabolic rate of [125I]HDL2 while the absolute catabolic rate appeared to be unchanged. Glucagon seems to be a potent hypolipidemic agent affecting mainly the apo E-rich lipoproteins. Its chronic administration limits lipoprotein accumulation which occurs upon cholesterol feeding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881241     DOI: 10.1007/bf02536072

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  31 in total

1.  Effect of glucagon on the serum lipids in essential hyperlipemia and in hypercholesterolemia.

Authors:  D S AMATUZIO; F GRANDE; S WADA
Journal:  Metabolism       Date:  1962-12       Impact factor: 8.694

2.  The synthesis of "chylomicronlike" bodies and maintenance of normal blood sugar levels by the isolated, perfused rat liver.

Authors:  R E KAY; C ENTENMAN
Journal:  J Biol Chem       Date:  1961-04       Impact factor: 5.157

3.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

4.  Activity of glucose-1-phosphate on liver steatosis.

Authors:  G GIALDRONI-GRASSI
Journal:  Nature       Date:  1958-01-04       Impact factor: 49.962

5.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

6.  Further studies concerning glucagon-induced hypocholesterolemia.

Authors:  S O Byers; M Friedman; S R Elek
Journal:  Proc Soc Exp Biol Med       Date:  1975-05

7.  Demonstration of a specific metabolic effect of dietary disaccharides in the rat.

Authors:  O E Michaelis; C S Nace; B Szepesi
Journal:  J Nutr       Date:  1975-09       Impact factor: 4.798

8.  Cholesterol ester turnover in isolated liver cells. Effects of cholesterol feeding.

Authors:  D Mathe; K M Botham; G S Boyd
Journal:  Biochim Biophys Acta       Date:  1984-05-11

9.  Regulation of bile acid synthesis in cultured rat hepatocytes: stimulation by apoE-rich high density lipoproteins.

Authors:  A M Mackinnon; C A Drevon; T M Sand; R A Davis
Journal:  J Lipid Res       Date:  1987-07       Impact factor: 5.922

10.  Serum and hepatic nascent lipoproteins in normal and hypercholesterolemic rats.

Authors:  P J Dolphin
Journal:  J Lipid Res       Date:  1981-08       Impact factor: 5.922

View more
  12 in total

1.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

Review 2.  The alpha-cell as target for type 2 diabetes therapy.

Authors:  Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1.

Authors:  Toshiyuki Nakamura; Norihito Shibata; Takako Nishimoto-Shibata; Dongdong Feng; Mamoru Ikemoto; Kiyoto Motojima; Naoyuki Iso-O; Kazuhisa Tsukamoto; Masafumi Tsujimoto; Hiroyuki Arai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-08       Impact factor: 11.205

Review 4.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

5.  Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression.

Authors:  Shelly R Nason; Teayoun Kim; Jessica P Antipenko; Brian Finan; Richard DiMarchi; Chad S Hunter; Kirk M Habegger
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

6.  Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo.

Authors:  M Rudling; B Angelin
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

7.  Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans.

Authors:  Changting Xiao; Mirjana Pavlic; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

8.  Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes.

Authors:  Md Kamrul Hasan Chowdhury; Nigel Turner; Nicholas L Bentley; Abhirup Das; Lindsay E Wu; Dulama Richani; Sonia Bustamante; Robert B Gilchrist; Margaret J Morris; Peter R Shepherd; Greg C Smith
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

9.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

10.  Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.

Authors:  Cristina B Guzman; Suman Duvvuru; Anthony Akkari; Pallav Bhatnagar; Chakib Battioui; Wendra Foster; Xiaotian Michelle Zhang; Sudha S Shankar; Mark A Deeg; Naga Chalasani; Thomas A Hardy; Christof M Kazda; Sreekumar G Pillai
Journal:  Hepatol Commun       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.